

Defendants' Exhibit List (Ex. A)

Case # 2:16-cv-02525-MMD-NJK

Caption: Amarin Pharma, Inc. v. Hikma Pharmaceuticals USA, Inc., et al.

Exhibits for: Defendants Hikma Pharmaceuticals USA, Inc.; Hikma Pharmaceuticals International Limited; Dr. Reddy's Laboratories, Inc.; and Dr. Reddy's Laboratories, Ltd.

Date Marked	Date Admitted	Number	Witness	Description
1/8/2020	1/13/2020	1500		U.S. Patent No. 8,293,728 (AMRN-PEXP-0000001-22) Stipulated - same as 21
1/8/2020	1/13/2020	1501		U.S. Patent No. 8,293,728 File History (AMRN00206053-212773) Same as 39 Stipulated
1/8/2020	1/13/2020	1502		U.S. Patent No. 8,318,715 (AMRN-PEXP-0000023-45) Stipulated
1/8/2020	1/13/2020	1503		U.S. Patent No. 8,318,715 File History (AMRN00212774-19280) Same as 40 Stipulated
1/8/2020	1/13/2020	1504		U.S. Patent No. 8,357,677 (AMRN-PEXP-0000046-67) Same as 25 Stipulated
1/8/2020	1/13/2020	1505		U.S. Patent No. 8,357,677 File History (AMRN00219281-25724) Same as 41 Stipulated

Date Marked	Date Admitted	Number	Witness	Description
1/8/2020	1/13/2020	1506		U.S. Patent No. 8,367,652 (AMRN-PEXP-0000068-90)
<i>Same as 26 Stipulated</i>				
1/8/2020	1/13/2020	1507		U.S. Patent No. 8,367,652 File History (AMRN00225725-32139)
<i>Same as 42 Stipulated</i>				
1/8/2020	1/13/2020	1508		U.S. Patent No. 8,377,920 (AMRN-PEXP-0000091-113)
<i>Same as 27 Stipulated</i>				
1/8/2020		1509		U.S. Patent No. 8,377,920 File History (AMRN00232140-9831)
1/8/2020	1/13/2020	1510		U.S. Patent No. 8,399,446 (AMRN-PEXP-0000114-36)
<i>Same as 28 Stipulated</i>				
1/8/2020		1511		U.S. Patent No. 8,399,446 File History (AMRN00239832-47573)
1/8/2020	1/13/2020	1512		U.S. Patent No. 8,415,335 (AMRN-PEXP-0000137-60)
<i>Same as 29 Stipulated</i>				
1/8/2020		1513		U.S. Patent No. 8,415,335 File History (AMRN00247574-55303)

Date Marked	Date Admitted	Number	Witness	Description
1/8/2020	1/13/2020	1514		U.S. Patent No. 8,431,560 (AMRN-PEXP-0000161-83)
<i>Same as 30 Stipulated</i>				
1/8/2020	1/13/2020	1515		U.S. Patent No. 8,431,560 File History (AMRN00263074-71241)
<i>Same as 50 Stipulated</i>				
1/8/2020	1/13/2020	1516		U.S. Patent No. 8,518,929 (AMRN-PEXP-0000184-206)
<i>Same as 31 Stipulated</i>				
1/8/2020	1/13/2020	1517		U.S. Patent No. 8,518,929 File History (AMRN00287378-988)
<i>Same as 51 Stipulated</i>				
1/8/2020	1/13/2020	1518		U.S. Patent No. 8,524,698 (AMRN-PEXP-0000207-30)
<i>Same as 32 Stipulated</i>				
1/8/2020		1519		U.S. Patent No. 8,524,698 File History (AMRN00287989-8608)
<i>Stipulated</i>				
1/8/2020	1/13/2020	1520		U.S. Patent No. 8,293,727 (AMRN03061427-47)
<i>Stipulated</i>				
1/8/2020	1/13/2020	1521		U.S. Patent No. 8,293,727 File History (AMRN03058106-9969)
<i>Stipulated - same as 30</i>				

Date Marked	Date Admitted	Number	Witness	Description
1/8/2020 AS	1/13/2020	1522		U.S. Provisional Application Nos. 61/151,291 (AMRN00204453-503) <i>Stipulated</i>
1/8/2020	1/13/2020	1523		U.S. Provisional Application Nos. 61/173,755 (AMRN00204504-557) <i>Stipulated</i>
1/8/2020 1/15/2020	1/15/2020	1524	Heinecke	WO 2007/142118 and English translation (ICOSAPENT_DFNDTS00007058-107)
1/8/2020	1/13/2020	1525		WO 2008/004900 (ICOSAPENT_DFNDTS00007108-50) <i>Stipulated</i>
1/8/2020	1/13/2020	1526		National Institutes of Health, National Heart, Lung, and Blood Institute, "Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III, Executive Summary," May 2001) (ICOSAPENT_DFNDTS00006549-87) <i>Same as 913 - Stipulated</i>
1/8/2020 1/13/2020	1/13/2020	1527		"Epadel Capsules 300, Japan Pharmaceutical Reference 369 (2nd ed. 1991) (ICOSAPENT_DFNDTS00006169-73) <i>Stipulated</i>
1/8/2020	1/13/2020	1528		Epadel Capsules 300, January 2007 Update (Version 5) (ICOSAPENT_DFNDTS00008961-969) <i>Stipulated</i>
1/8/2020	1/13/2020	1529		Geppert et al., Microalgal Docosahexaenoic Acid Decreases <i>Same as 909 Stipulated</i>

Date Marked	Date Admitted	Number	Witness	Description
				Plasma Triacylglycerol in Normolipidaemic Vegetarians: A Randomized Trial, 95 BRIT. J. NUTRITION 779 (2006) (ICOSAPENT_DFNDTS00006126-35)
1/8/2020	1/13/2020	1530		"Grimsgaard et al., Highly Purified Eicosapentaenoic Acid and Docosahexaenoic Acid in Humans Have Similar Triacylglycerol-Lowering Effects but Divergent Effects on Serum Fatty Acids, 66 AM. J. CLIN. NUTR. 649-59 (1997) (ICOSAPENT_DFNDTS00006136-46)
	Same as 967 Stipulated			
1/8/2020	1/13/2020	1531		Harris et al., Safety and Efficacy of Omacor in Severe Hypertriglyceridemia, J. CARDIOV. RISK, 4:385-391 (1997) (ICOSAPENT_DFNDTS00006152-58)
	same as 436 Stipulated			
1/8/2020	1/13/2020	1532		Hayashi et al., Decreases in Plasma Lipid Content and Thrombotic Activity by Ethyl Icosapentate Purified from Fish Oils, 56(1) CURR. THERAP. RES. 24-31 (1995) (ICOSAPENT_DFNDTS00006159-68)
	Stipulated			
1/8/2020	1/13/2020	1533		Katayama et al., Efficacy and Safety of Ethyl Icosapentate (Epadel®) Given for a Long Term Against Hyperlipidemia, 21 PROG. MED. 457 (2001) and English translation (ICOSAPENT_DFNDTS00006174-6200)
	Stipulated			
1/8/2020	1/13/2020	1534		Kurabayashi et al., Eicosapentaenoic Acid Effect on Hyperlipidemia in Menopausal Japanese Women, OBSTET. GYNECOL. 96:521-8 (2000) (ICOSAPENT_DFNDTS00006237-44)
	Stipulated - Same as 376			
1/8/2020	1/13/2020	1535		Lovaza®, Physicians' Desk Reference 2699 (62d ed. 2007)
	same as 1034 Stipulated			

Date Marked	Date Admitted	Number	Witness	Description
				(ICOSAPENT_DFNDTS00006710-13)
1/8/2020	1/13/2020	1536		Maki et al., Lipid responses to a dietary docosahexaenoic acid supplement in men and women with below average levels of high density lipoprotein cholesterol, 24 J. AM. COL. NUTR. 189-99 (2005) (ICOSAPENT_DFNDTS00006426-36)
<i>Stipulated</i>				
1/8/2020	1/13/2020	1537		Matsuzawa et al., Effect of Long-Term Administration of Ethyl Icosapentate (MND-21) in Hyperlipidaemic Patients, 7 J. CLIN. THERAPEUTIC & MEDICINES 1801 (1991) and English translation (ICOSAPENT_DFNDTS00006440-96)
1/8/2020	1/13/2020	1538	Ketchum	Mori et al., Purified Eicosapentaenoic and Docosahexaenoic Acids Have Differential Effects on Serum Lipids and Lipoproteins, LDL Particle Size, Glucose, and Insulin in Mildly Hyperlipidemic Men, 71 AM. J. CLINICAL NUTRITION 1085 (2000) (ICOSAPENT_DFNDTS00011026-35)
1/8/2020	1/28/2020	1539	Toth	Nakamura et al., Joint Effects of HMG-CoA Reductase Inhibitors and Eicosapentaenoic Acids on Serum Lipid Profile and Plasma Fatty Acid Concentrations in Patients with Hyperlipidemia, 29(1) INT. J. CLIN. LAB. RES. 22-25 (1999) (ICOSAPENT_DFNDTS00006540-43)
1/8/2020	1/13/2020	1540		Nestel et al., The n-3 fatty acids eicosapentaenoic acid and docosahexaenoic acid increase systemic arterial compliance in humans. 76 AM. J. CLIN. NUTR. 326 (2002) (ICOSAPENT_DFNDTS00006544-48)
<i>Same as 912 Stipulated</i>				

Date Marked	Date Admitted	Number	Witness	Description
1/8/2020	1/13/2020	1541		Nozaki et al., Effects of Purified Eicosapentaenoic Acid Ethyl Ester on Plasma Lipoproteins in Primary Hypercholesterolemia, 62 INT'L J. VITAMIN & NUTRITION RES. 256-60 (1992) (ICOSAPENT_DFNDTS00006588-94)
1/8/2020	1/13/2020	1542		Okumura et al., Eicosapentaenoic Acid Improves Endothelial Function in Hypertriglyceridemic Subjects Despite Increased Lipid Oxidizability, 324 AM. J. MED. SCI. 247-53 (2002) (ICOSAPENT_DFNDTS00006595-6601)
1/8/2020		1543		Omacor® Label (2004) (ICOSAPENT_DFNDTS00006618-26)
1/8/2020		1544		Omacor®, Physicians' Desk Reference 2735 (60d ed. 2006) (ICOSAPENT_DFNDTS00006714-17)
1/8/2020	1/28/2020	1545	Toth	Park & Harris, Omega-3 Fatty Acid Supplementation Accelerates Chylomicron Triglyceride Clearance, 44 J. LIPID RES. 44:455-463 (2003) (ICOSAPENT_DFNDTS00006701-6709)
1/8/2020	1/15/2020	1546	Heineke	Saito et al., Results of Clinical Usage of Improved Formulation (MND-21S) Epadel Capsule 300 with Respect to Hyperlipidemia, 26(12) JPN. PHARMACOL. THER. 2047-62 (1998) and English translation (ICOSAPENT_DFNDTS00006791-6823)
1/8/2020	1/28/2020	1547	Toth	Saito et al., Effects of EPA on Coronary Artery Disease in

Date Marked	Date Admitted	Number	Witness	Description
				Hypercholesterolemic Patients with Multiple Risk Factors: Sub-Analysis of Primary Prevention Cases from the Japan EPA Lipid Intervention Study (JELIS), 200 ATHEROSCLEROSIS 135-40 (2008) (ICOSAPENT_DFNDTS00006785-90)
1/8/2020	1/13/2020	1548		Satoh et al., Purified Eicosapentaenoic Acid Reduces Small Dense LDL, Remnant Lipoprotein Particles, and C-Reactive Protein in Metabolic Syndrome, 30 DIABETES CARE 144 (2007) (ICOSAPENT_DFNDTS00006832-36)
1/8/2020	1/13/2020	1549		Shinozaki et al., The Long-Term Effect of Eicosapentaenoic Acid on Serum Levels of Lipoprotein (a) and Lipids in Patients with Vascular Disease, 2(2) J. ATHEROSCL. THROMB. 107-09 (1996) (ICOSAPENT_DFNDTS00011751-3)
1/8/2020	1/13/2020	1550		Takaku et al., Study on the Efficacy and Safety of Ethyl Icosapentate (MND-21) in Treatment of Hyperlipidemia Based on a Long-Term Administration Test, 7 J. CLIN. THERAPEUTICS & MEDICINE 191 (1991) and English translation (ICOSAPENT_DFNDTS00006864-6904)
1/8/2020	1/13/2020	1551		Wojenski et al., Eicosapentaenoic Acid Ethyl Ester as an Antithrombotic Agent: Comparison to an Extract of Fish Oil, BIOCHIM. BIOPHYS. ACTA., 1081(1):33-38 (1991) (ICOSAPENT_DFNDTS00014511-6)
1/8/2020	1/13/2020	1552		Yokoyama et al., Effects of eicosapentaenoic acid on cardiovascular events in Japanese patients with hypercholesterolemia: Rationale, design, and baseline characteristics of the Japan EPA Lipid Intervention Study (JELIS), 146 AM.

Date Marked	Date Admitted	Number	Witness	Description
				HEART J. 613-20 (2003) (ICOSAPENT_DFNDTS00007166-73)
1/8/2020	1/13/2020	1553		Yokoyama et al., Effects of Eicosapentaenoic Acid on Major Coronary Events in Hypercholesterolaemic Patients (JELIS): a Randomized Open-Label, Blinded Endpoint Analysis, 369 LANCET 1090-98 (2007) (ICOSAPENT_DFNDTS00007157-65)
<i>Speculated</i>				
1/8/2020	1/14/2020	1554	Budoff	Opening Expert Report of Matthew Budoff, M.D., Regarding Hikma's ANDA product and Vascepa® with Exhibits A-C
1/8/2020		1555		Opening Expert Report of Matthew Budoff, M.D., Regarding DRL's ANDA product and Vascepa®
1/8/2020		1556		Reply Expert Report of Matthew Budoff, M.D., Regarding Defendants' ANDA Products and Vascepa® and Exhibits A-B
1/8/2020		1557		Email between Ketchum and Budoff re Vascepa (icosapent ethyl) [formerly AMR101]: Congressional Heart and Stroke Coalition (AMRN02712524-26)
1/8/2020	1/13/2020	1558	Ketchum	FDA Complete Response, NDA 202057/S-005 (AMRN03132005-09)
1/8/2020		1559		Dollars for Docs: 2015 Edition

Date Marked	Date Admitted	Number	Witness	Description
1/8/2020		1560		OpenPaymentsData.CMS.gov 2016 data for Matthew J. Budoff Summary
1/8/2020		1561		OpenPaymentsData.CMS.gov 2016 data for Matthew J. Budoff General Payments
1/8/2020		1562		OpenPaymentsData.CMS.gov 2017 data for Matthew J. Budoff General Payments
1/8/2020		1563		OpenPaymentsData.CMS.gov 2018 data for Matthew J. Budoff General Payments
1/8/2020		1564		Investigator Services Agreement (AMRN03171996-2021)
1/8/2020		1565		Amendment #1 to Investigator Services Agreement (AMRN03172022-29)
1/8/2020		1566		Amendment #2 to Investigator Services Agreement (AMRN03172030-34)
1/8/2020		1567		Amendment #3 to Investigator Services Agreement (AMRN03172035-42)

Date Marked	Date Admitted	Number	Witness	Description
1/8/2020		1568		Amendment to Speaker Services Agreement of 2014 (AMRN03172043)
1/8/2020		1569		Services Agreement (AMRN03172044-48)
1/8/2020		1570		Services Agreement (AMRN03172049-51)
1/8/2020		1571		Consultancy Agreement (AMRN03172052-60)
1/8/2020		1572		Amarin Mutual Confidentiality Agreement (AMRN03172061-64)
1/8/2020		1573		Consultancy Agreement (AMRN03172065-73)
1/17/2020		1574	Fisher	Responsive Expert Report of Edward A. Fisher, M.D., M.P.H., Ph.D.
1/8/2020		1575		List of Materials Considered by Dr. Edward A. Fisher

Date Marked	Date Admitted	Number	Witness	Description
1/8/2020		1576		Curriculum Vitae of Edward A. Fisher, M.D., M.P.H., Ph.D.
1/8/2020		1577		Feingold and Grunfeld, Diabetes and Dyslipidemia. NCBI Bookshelf. https://www.ncbi.nlm.nih.gov/books/NBK305900/?report=printable (last accessed 06/25/2019)
1/8/2020 <i>1/14/2020</i>	<i>1/14/2020</i>	1578	<i>Budoff</i>	Lovaza® Label (AMRN01187779-80)
1/8/2020		1579		Chapman, et al. Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management. European Heart Journal 32:1345-1361 (2011).
1/8/2020		1580		American Diabetes Association, 10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes – 2019. Diabetes Care 42(1): S103-S123 (January 2019). (AMRN-PEXP-0008656-81)
1/8/2020 <i>1/15/2020</i>	<i>1/15/2020</i>	1581	<i>Heineker</i>	O’Riordan, MARINE: Ethyl-EPA Reduces Triglyceride Levels Without Raising LDL Cholesterol. www.medscape.com (November 30, 2010). (AMRN00291600-602)
1/8/2020		1582		Siscovick, et al. Omega-3 Polyunsaturated Fatty Acid (Fish Oil) Supplementation and the Prevention of Clinical Cardiovascular Disease: A Science Advisory From the American Heart Association. Circulation

Date Marked	Date Admitted	Number	Witness	Description
				135:e867-e8884 (2017). (ICOSAPENT_DFNDTS00018006-23)
1/8/2020		1583		Reply Expert Report of Nicholas P. Godici with Exhibits A-C.
1/8/2020		1584		Expert Report of Stephen G. Kunin
1/8/2020		1585		Non-Final Rejection, U.S. Patent Application No. 12/702,889. (AMRN03058824-35)
1/8/2020		1586		Response to the Office Action Dated June 20, 2011, U.S. Patent Application No. 12/702,889. (AMRN03058867-907)
1/8/2020 1/15/2020	1/15/2020	1587	Heineke	Final Rejection, U.S. Patent Application No. 12/702,889. (AMRN03059004-28)
1/8/2020 1/15/2020	1/16/2020	1588	Heineke	Non-Final Rejection, U.S. Patent Application No. 12/702,889. (AMRN03059744-69)
1/8/2020 1/13/2020		1589		Declaration of Philip Lavin under 37 C.F.R. §1.132, U.S. Patent Application No. 12/702,889. (AMRN03059830-34) stipulated
1/8/2020		1590		Interview Agenda and Summary, U.S. Patent Application No. 12/702,889.

Date Marked	Date Admitted	Number	Witness	Description
				(AMRN03059782-88)
1/8/2020	1/13/2020	1591		Notice of Allowance, U.S. Patent Application No. 12/702,889. (AMRN03059927-40)
<i>Same as 380 Stipulated</i>				
1/8/2020		1592		37 CFR 1.104 Nature of examination Rev. 5, Aug. 2006
1/8/2020		1593		Declaration III of Harold E. Bays Under 37 C.F.R. § 1.132, U.S. Patent Application No. 12/702,889. (AMRN03059815-23)
1/8/2020		1594		In Limine Order Granting Defendant Medtronic's Motion to Exclude the Testimony of Nicholas Godici, Barry v. Medtronic. E.D. Tex. No. 1:14-cv-104
1/8/2020		1595		Opening Expert Report of Jay W. Heinecke, M.D. on Invalidity of the Asserted Claims of the Patents-In-Suit with Exhibits 1-2.
1/8/2020		1596		Rebuttal Expert Report of Jay W. Heinecke, M.D. on Invalidity of the Asserted Claims of the Patents-In-Suit with Materials Considered
1/8/2020 1/15/2020	1	1597	<i>Heinecke</i>	Reply Expert Report of Jay W. Heinecke, M.D. on invalidity of the Asserted Claims of the Patents-In-Suit with Materials Considered
1/8/2020	1/13/2020	1598		TRICOR® Approved Labeling (AMRN-PEXP-0001915-32)

SAME AS 380 Stipulated

Date Marked	Date Admitted	Number	Witness	Description
1/8/2020		1599		Niaspan® Label (AMRN-PEXP-0001692-1712)
1/8/2020	1/13/2020	1600	Same as 1026 Stipulated	Carlson, et al. ON the Rise in Low Density and High Density Lipoproteins in Response to the Treatment of Hypertriglyceridaemia in Type IV and Type V Hyperlipoproteinemia. Atherosclerosis 26:603-609 (1977). (AMRN-PEXP-0008180-86)
1/8/2020	1/13/2020	1601	Same as 385 Stipulated	Isley, et al. Pilot study of combined therapy with w-3 fatty acids and niacin in atherogenic dyslipidemia, Journal of Clinical Lipidology 1:211-217 (2007). (AMRN-PEXP-00621043-49)
1/8/2020		1602		Mitchell, Peter. Regulator rebuffs Merck's cholesterol drug. chernistryworld.com/news/regulator-rebuffs-rnercks-cholesterol-di-ug/3003426.article (AMRN-PEXP-0009429-31)
1/8/2020		1603		European Medicines Agency press release, Tredaptive, Pelzont and Trevaclyn suspended across the EU. (AMRN-PEXP-0009110-12)
1/8/2020	1/15/2020	1604	Heinecke	Oram and Heinecke, When Good Cholesterol Turns Bad: The Evolving Saga of CETP Inhibitors and Clinical Strategies to Elevate High-density Lipoprotein. Current Atherosclerosis Reports 9:425-427 (2007).
1/8/2020	1/15/2020	1605	Heinecke	Schacky, A review of omega-3 ethyl esters for cardiovascular prevention

Date Marked	Date Admitted	Number	Witness	Description
				and treatment of increased blood triglyceride levels. Vascular Health and Risk Management 2(3):251-262 (2006). (AMRN-PEXP-0007466-77)
1/8/2020 1/21/2020		1606	Hofmann	Rebuttal Expert Report of Ivan T. Hofmann with Appendices 1-3
1/8/2020 1/21/2020	1/21/2020	1607	Hofmann	Spreadsheet: Treatment Insights View (AMRN-PEXP-0007104)
1/8/2020		1608		Spreadsheet: Historical Revenue Historical Revenue Q1 2013-Q4 2018 (AMRN03171431)
1/8/2020		1609		Spreadsheet: Rx View (AMRN-PEXP-0007102)
1/8/2020		1610		Opening Expert Report of Firhaad Ismail, M.D., F.A.C.E. with Exhibits A-B
1/8/2020		1611		Corrected Opening Expert Report of Firhaad Ismail, M.D., F.A.C.E.
1/8/2020		1612		Reply Expert Report of Firhaad Ismail, M.D., F.A.C.E. with Exhibit A

Date Marked	Date Admitted	Number	Witness	Description
1/8/2020		1613		Speaker Services Agreement (AMRN03171905-13)
1/8/2020		1614		2014 Speaker Contract (AMRN03171896-1904)
1/8/2020		1615		Speaker Services Agreement (AMRN03171914-20)
1/8/2020		1616		2016 Speaker Services Agreement (AMRN03171921-26)
1/8/2020		1617		Ornstein, et al. Dollars for Doctors. Docs on Pharma Payroll Have Blemished Records, Limited Credentials. https://www.propublica.org/article/dollars-to-doctors-physician-disciplinary-records# (last accessed 6/11/19)
1/8/2020		1618		Dollars for Docs, Top Earners. https://web.archive.org/web/20110715123145/http://projects.propublica.org/docdollars/top_earners
1/8/2020		1619		State of Nevada Pharmacy & Therapeutics Committee Meeting Minutes
1/8/2020		1620		Email between Riedell and Meehan re Summary & Next Steps: Vascepa

Date Marked	Date Admitted	Number	Witness	Description
				Speaker Programs (AMRN00974580)
1/8/2020		1621		Spreadsheet: Controlled List Speakers 05172011 (AMRN00974582)
				Email between Padmanabhan and Budsock (AMRN02390922)
1/8/2020		1623		Spreadsheet of consultant payments (AMRN02390926)
1/8/2020 <u>1/17/2020</u>	<u>1/17/2020</u>	1624	<i>Fisher</i>	Tajuddin, et al. Prescription omega-3 fatty acid products: considerations for patients with diabetes mellitus. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2016;9:109-118. (AMRN-PEXP-0001808-17.)
1/8/2020		1625		Reply Expert Report of John Kornak, Ph.D. with Exhibits A-B
				Corrected Reply Expert Report of John Kornak, Ph.D. with Exhibits A-B
1/8/2020		1627		Redlined Corrected Reply Expert Report of John Kornak, Ph.D. with Exhibits A-B

Date Marked	Date Admitted	Number	Witness	Description
1/8/2020		1628		document titled <u>lavinV3</u> <u>ICOSAPENT_DFNDT 00020685.R</u>
1/8/2020		1629		document titled <u>reportPlots</u> <u>ICOSAPENT_DFNDT 00020684.R</u>
1/8/2020		1630		document titled <u>lavinV5</u> <u>ICOSAPENT_DFNDT 00020683.R</u>
1/8/2020		1631		document titled <u>lavinV5</u> <u>ICOSAPENT_DFNDT 00020683.R</u> Calculations
1/8/2020 <u>1/14/2020</u>	<u>1/14/2020</u>	1632	<u>Budoff</u>	Miller, et al. Triglycerides and Cardiovascular Disease: A Scientific Statement From the American Heart Association. Circulation 123:2292- 2333 (2011). (<u>ICOSAPENT_DFNDT00020641-82</u>)
1/8/2020		1633		Carroll, et al. Trends in Lipids and Lipoproteins in U.S. Adults, 1988- 2010. JAMA 308(15):1545-54 (2012). (<u>ICOSAPENT_DFNDT00020631-40</u>)
1/8/2020		1634		Expert Report of Stephen G. Kunin with Exhibits A-D
1/8/2020		1635		Interview Agenda, Applicant Initiated Interview Summary, Response to Non-

Date Marked	Date Admitted	Number	Witness	Description
				Final Office Action Dated March 2, 2012 U.S. Patent Application No. 12/702,889. (AMRN03059780-814)
1/8/2020		1636		Response to Non-Final Action Dated April 4, 2012, U.S. Patent Application No. 13/349,153. (AMRN00212303-389)
				Declaration of Philip Lavin Under 37 C.F.R. §1.132, U.S. Patent Application No. 12/702,889. (AMRN03059338-58)
1/8/2020	11/3/2020	1637		Curriculum Vitae, Dr. R. Preston Mason (AMRN-PEXP-0000546-569)
				Opening Expert Report of R. Preston Mason, Ph.D. with Appendix A and Exhibits A-B
1/8/2020		1639		Reply Expert Report of R. Preston Mason, Ph.D. with Exhibit A
				Bhatt, et al. Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia. N Engl J Med 380(1):11-22 (January 3, 2019) (AMRN-PEXP-0000689-700)
1/8/2020	11/15/2020	1641	Heincke	Mason and Jacob, Eicosapentaenoic acid inhibits glucose-induced membrane cholesterol crystalline domain formation through a potent antioxidant mechanism. Biochimica et Biophysica Acta 1848:502-509 (2015).

Date Marked	Date Admitted	Number	Witness	Description
1/8/2020		1643		Mason and Jacob, Eicosapentaenoic acid inhibits glucose-induced membrane cholesterol crystalline domain formation through a potent antioxidant mechanism, version with track changes.(AMRN01366206-34)
1/8/2020		1644		Email between Stirtan and Mason re RP Mason Draft manuscript: EPA vs. DHA and TG-lowering agents (antioxidation, Cholesterol Domains) – AMRN comments (AMRN01366205)
1/8/2020		1645		Mason, et al. Eicosapentaenoic acid reduces membrane fluidity, inhibits cholesterol domain formation, and normalizes bilayer width in atherosclerotic-like model membranes. Biochimica et Biophysica Acta 1858:3131-3140 (2016). (AMRN03146567-76)
1/8/2020		1646		Mason, et al. Eicosapentaenoic acid improves endothelial function and nitric oxide bioavailability in a manner that is enhanced in combination with a statin. Biomedicine & Pharmacotherapy 103:1231-1237 (2018). (AMRN-PEXP-0000539-45)
1/8/2020		1647		Email between Mason and Rowe re CDA (AMRN02187308-9)
1/8/2020		1648		Amarin Confidentiality Agreement (AMRN03171738-40)
1/8/2020		1649		Self-Medlin, et al. Glucose promotes membrane cholesterol crystalline

Date Marked	Date Admitted	Number	Witness	Description
				domain formation by lipid peroxidation. Biochimica et Biophysica Acta xxx:xxx-xxx (2009) (AMRN02187310-15)
1/8/2020		1650		Email between Mason and Rowe re agreement (AMRN02187316)
1/8/2020		1651		Email between Soni, Rowe, Stirfan, Grandolfi, Manku, and Doogan re Amarin 2009 Project Protocol (AMRN01636840-41)
1/8/2020		1652		Effects of Eicosapentaenoic Acid (EPA) and Docosahexaenoic Acid (DHA) on Lipid Peroxidation and Membrane Structural Organization (AMRN02188384-88)
1/8/2020		1653		Email between Rowe and Mason re JELIS studies(AMRN00769425)
1/8/2020		1654		Email between Bress and Stirfan re Preston Mason Work-Order: For sign-off (AMRN00799606)
1/8/2020		1655		Mason and Jacob Research proposal: Comparative Effects of Eicosapentaenoic Acid (EPA), Docosahexanoic Acid (DHA), Fenofibrate, Niacin, Gemfibrozil – Alone or in Combination with Atorvastatin Metabolite – on Human Endothelial Function Following Exposure to oxLDL (AMRN00799607)
1/8/2020		1656		Email between Ketchum and Thero re Preston Mason: Important publication

Date Marked	Date Admitted	Number	Witness	Description
				development that involves addt'l funding (AMRN01434884-88)
1/8/2020		1657		Email between Mason and Stirtan re ACC-Meeting with Preston Mason (2 pm Sat, Hyatt at Convention Center) (AMRN02915248-54)
1/8/2020		1658		Email between Mason and Stirtan re ACC-Meeting with Preston Mason (2 pm Sat, Hyatt at Convention Center) (AMRN00389762-64)
1/8/2020		1659		Mason, EPA Enhanced Nitric Oxide Bioavailability: Potential Synergistic Actions with Statins. (AMRN00389765-86)
1/8/2020		1660		Services Agreement (AMRN003171846-48)
1/8/2020		1661		Services Agreement (AMRN003171757-59)
1/8/2020		1662		Services Agreement (AMRN003171752-56)
1/8/2020		1663		Services Agreement (AMRN003171732-34)
1/8/2020		1664		Services Agreement (AMRN003171791-95)

Date Marked	Date Admitted	Number	Witness	Description
1/8/2020		1665		Consultancy Agreement (AMRN003171743-51)
1/8/2020		1666		Facsimile from Mason to Mandura attaching W-9 and Consultancy Agreement(AMRN003171796-804)
1/8/2020		1667		Getler, No Compliments for 'Supplements'. https://www.pbs.org/publiceditor/blogs/lombudsman/2016/02/04/no-compliments-for-supplements/ last accessed June 13, 2019
1/8/2020		1668		Mason, et al. Omega-3 fatty acid fish oil dietary supplements contain saturated fats and oxidized lipids that may interfere with their intended biological benefits. Biochemical and Biophysical Research Communications 483:425-429 (2017).
1/8/2020		1669		Email between Soni, Stirton, and Braeckman re Follow up from AHA on human endothelial function and nitric oxide studies – [From Preston Mason -- Confidential] (AMRN002752198-2210)
1/8/2020		1670		U.S. Patent Application Publication 2014/0249225 A1
1/8/2020		1671		U.S. Patent 10,172,818 B2

Date Marked	Date Admitted	Number	Witness	Description
1/8/2020		1672		Email between Mason and Stirtan re Summary of New Findings with EPA with attachment (AMRN002305585-86)
1/8/2020		1673		Rebuttal Expert Report of Peter R. Mathers on Non-Infringement of the Asserted Claims of the Patents-in-Suit
1/8/2020		1674		Materials Considered in Rebuttal Expert Report of Peter R. Mathers on Non-Infringement of the Asserted Claims of the Patents-In-Suit
1/8/2020		1675		Peter R. Mathers Bio
1/8/2020		1676		Final Printed Carton and Container Labels for approved NDA 202057/S-019 (AMRN03132168-77)
1/8/2020		1677		FDA, Distributing Scientific and Medical Publications on Unapproved and New Uses— Recommend Practices: Guidance for Industry (2014) (“FDA Unapproved Use Guidance”) (ICOSAPENT_DFNDT00018232-51)
1/8/2020 1/28/2020	1/28/2020	1678		Guidance for Industry, Clinical Studies Section of Labeling for Human Prescription Drug and Biological Products – Content and Format(AMRN-PEXP-0010229-241)

Date Marked	Date Admitted	Number	Witness	Description
1/8/2020 1/14/2020	1/14/2020	1679	scheinberg	Lovenox label (ICOSAPENT_DFNDT00015711-51)
1/8/2020		1680		Eliquis® Label (AMRN-PEXP-0009835-79)
1/8/2020 1/28/2020	1/28/2020	1681		FDA, Indications and Usage Section of Labeling for Human Prescription Drug and Biological Products —Content and Format: Guidance for Industry, at 10 (2018) (“FDA Labeling Guidance”) (AMRN-PEXP-0010242-261)
1/8/2020 1/28/2020	1/28/2020	1682		Guidance for Industry, Clinical Studies Section of Labeling for Human Prescription Drug and Biological Products – Content and Format (AMRN-PEXP-0010187)
1/8/2020		1683		Expert Report of Sean Nicholson with Appendices A-E and Exhibits 1-31B
1/8/2020 1/21/2020		1684	Nicholson	Reply Expert Report of Sean Nicholson with Appendixes A-D and Exhibits 1-6 <u>exh 2 of 1684</u>
1/8/2020		1685	Nicholson	Beatty, Joel, and Shawn M Egan, “Amarin Corp (AMRN) 2019 Revenue Guidance Lower Than Expectations, TP \$20 (-\$8),” Citi Research (AMRN-PEXP-0007707-17)
1/8/2020		1686		Berndt, The U.S. Pharmaceutical Industry: Why Major Growth In Times

Date Marked	Date Admitted	Number	Witness	Description
				of Cost Containment? Health Affairs 20(2):100-114 (Mar/Apr 2001) (AMRN-PEXP-0002182-96)
1/8/2020		1687		Berndt, et al. Information, Marketing, and Pricing in the U.S. Antiulcer Drug Market. The American Economic Review 85(2): 100-105 (May 1995) (AMRN-PEXP-0002272-78)
1/8/2020		1688		Cutler and McClellan, Is Technological Change in Medicine Worth? Health Affairs 20(5): 11-29 (Sept/Oct 2001)(AMRN-PEXP-0002402-20)
1/8/2020		1689		Reply Expert Report of Carl C. Peck, M.D.
1/8/2020		1690		Carl C. Peck, M.D. Prior Testimony
1/8/2020		1691		Materials Considered by C. Peck, M.D., June 10, 2019 Reply Expert Report
1/8/2020		1692		Curriculum Vitae, Carl C. Peck, M.D., Dr. h.c. (Uppsala)
1/8/2020		1693		21 C.F.R. §201.57 (ICOSAPENT_DFNDT00018074-94)
1/8/2020	1/13/2020	1694		Clinical Study Report: A Phase 3, Multi-center, Placebo-Controlled,

Same as 807 - Stipulated

Date Marked	Date Admitted	Number	Witness	Description
				Randomized, Double-Blind, 12-Week Study With an Open-Label Extension to Evaluate the Efficacy and Safety of AMR101 in Patients With Fasting Triglyceride Levels?500 mg/dL and ?2000 mg/dL: The AMR101 MARINE Study. Results of the Double-Blind Treatment Period. Final Version. (AMRN00053457-54134)
1/8/2020		1695		Guidance for Industry, Clinical Studies Section of Labeling for Human Prescription Drug and Biological Products – Content and Format (ICOSAPENT_DFNDT00018207-31)
1/8/2020		1696		Vascepa advertisement, “Vascepa looks different because it is different.” (AMRN03149773-4)
1/8/2020 1/14/2020	10	1697	Scheinberg	Rebuttal Expert Report of Jonathan I. Scheinberg, M.D., F.A.C.C., on Noninfringement of the Asserted Claims of the Patents-in-Suit with Exhibits A-B
1/8/2020 1/13/2020	1/13/2020	1698		Vascepa label (AMRN03132168-77)
	same as 940		Stipulated	
1/8/2020 1/13/2020	1/13/2020	1699		Dr. Reddy's Icosapent Ethyl Capsules, .5 gram ANDA 1.14.1.2 Annotated Draft Labeling Text (DRLEEPA 0095591-647)
	Same as 574		Stipulated	
1/8/2020 1/13/2020	1/13/2020	1700		West-Ward Icosapent Ethyl Capsules label (WWICO-NV-002835-43)
	same as 274		Stipulated	
1/8/2020 1/13/2020	1/13/2020	1701		CDER Application Number 202057Orig1s000 Medical Review(s)
	same as 289		Stipulated	

Date Marked	Date Admitted	Number	Witness	Description
				(ICOSAPENT_DFNDT00015424-567)
1/8/2020		1702		Lovenox label (ICOSAPENT_DFNDT00015711-51)
1/8/2020		1703		Eliquis® label (AMRN-PEXP-0009062-9106)
1/8/2020		1704		Opening Expert Report of Peter Paul Toth, M.D., Ph.D. with Exhibits A-C
1/8/2020 1/28/2020		1705	Toth	Responsive Expert Report of Peter Toth, M.D., Ph.D. with Exhibits A-B
1/8/2020		1706		Reply Expert Report of Peter Toth, M.D., Ph.D. with Exhibit A
1/8/2020		1707		Mahley and Bersot, Drug Therapy for Hypercholesterolemia and Dyslipidemia. Chapter 36 in Goodman & Gilman's The Pharmaceutical Basis of Therapeutics, 10th Ed. (2001). (AMRN00290358-92)
1/8/2020		1708		Toth, et al. Clinical and economic outcomes in a real-world population of patients with elevated triglyceride levels. Atherosclerosis 237:790-797 (2014).
1/8/2020 1/28/2020	1/28/2020	1709	Toth	Transcript of Hypertriglyceridemia: Managing Triglycerides to Reduce

Date Marked	Date Admitted	Number	Witness	Description
				Cardiovascular Risk. https://www.medscape.org/viewarticle/839217_transcript , last accessed 06/30/2019.
1/8/2020		1710		Toth, et al. Drug Therapy for Hypertriglyceridemia; Fibrates and Omega-3 Fatty Acids. Curr Atheroscler Rep. 11(1):71-79 (Jan, 2009).
1/8/2020		1711		Consultancy Agreement (AMRN03171927-37)
1/8/2020		1712		Consultancy Agreement (AMRN03171938-46)
1/8/2020		1713		Consultancy Agreement (AMRN03171947-54)
1/8/2020		1714		Consultancy Agreement (AMRN03171955-62)
1/8/2020		1715		Consultancy Agreement(AMRN03171963-73)
1/8/2020		1716		Consultancy Agreement (AMRN03171974-84)

Date Marked	Date Admitted	Number	Witness	Description
1/8/2020		1717		Services Agreement (AMRN03171985-89)
1/8/2020		1718		Services Agreement (AMRN03171990-92)
1/8/2020		1719		Services Agreement (AMRN03171993-95)
1/8/2020		1720		Speaker Program Metrics & Utilization as of June 27, 2013 (AMRN02386752-54)
1/8/2020		1721		ProPublica Dollars for Docs, Peter Toth, 2013 Payment Breakdown, https://projects.propublica.org/docdollars/doctors/pid/266019 , last accessed 06/24/2019
1/8/2020		1722		ProPublica Dollars for Docs, Peter Toth, 2014 Payment Breakdown, https://projects.propublica.org/docdollars/doctors/pid/266019 , last accessed 06/24/2019
1/8/2020		1723		ProPublica Dollars for Docs, Peter Toth, 2015 Payment Breakdown, https://projects.propublica.org/docdollars/doctors/pid/266019 , last accessed 06/24/2019
1/8/2020		1724		ProPublica Dollars for Docs, Peter Toth, 2016 Payment Breakdown, https://projects.propublica.org/docdollars/doctors/pid/266019 , last accessed 06/24/2019

Date Marked	Date Admitted	Number	Witness	Description
1/8/2020		1725		Email between Toth and Everett re Ad-Board Follow Up (AMRN00305102-105)
1/8/2020		1726		Graham, 25 top-earning doctors in Illinois. https://www.chicagotribune.com/lifestyles/health/chi-na-docdollars-profiles-sidebar-htmlstory.html , last accessed 06/24/2019.
1/8/2020		1727		Giuliani, Local doctor is in ... the money. www.saukvalley.com/2014/04/08/local-doctor-is-in-the-money/acz259h/?xsl=/pri nl. xsl , last accessed 06/25/2019
1/8/2020		1728		Subpoena to Testify at a Deposition in a Civil Action directed to Harold E. Bays
1/8/2020		1729		Harold E. Bays 2018 Curriculum Vitae (HB-AMRN00000001-7)
1/8/2020 1/15/2020	1/15/2020	1730		Statement of Investigator with Harold Bays 2009 Curriculum Vitae (AMRN00009725-32)
1/8/2020 1/15/2020	1/15/2020	1731		Native Spreadsheet: Amarin Corp. Consultant Spend 2009-2011 (AMRN03022105)
1/8/2020 1/15/2020	1/15/2020	1732		Email between Elson and Ketchum re Ad Comm estimated expenses with

Date Marked	Date Admitted	Number	Witness	Description
				attached spreadsheet (AMRN01493345-6)
1/8/2020 <i>1/15/2020</i>	<i>1/15/2020</i>	1733		Email between Bays and Soni re Invitation to Attend Amarin Expert Panel Meeting in Boston, USA (AMRN01502780-2)
1/8/2020 <i>1/15/2020</i>	<i>1/15/2020</i>	1734		Email between Crutchley and Bays re Dr. Bays – Honorarium for Amarin Expert Panel Meeting in Boston (AMRN01635508)
1/8/2020 <i>1/15/2020</i>	<i>1/15/2020</i>	1735		Email between Crutchley, Soni, Wicker, Osterloh, and Manku re Status Update Amarin Expert Panel Meeting – December 11-12 (AMRN01519654-5)
1/8/2020 <i>1/15/2020</i>	<i>1/15/2020</i>	1736		Group Exhibit:1) Bays, Rationale for Prescription Omega-3-Acid Ethyl Ester Therapy for Hypertriglyceridemia: A Primer for Clinicians. Drugs of Today 44(3): 205-246 (2008);2) Lovaza Label;3) Yokoyama, et al. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomized open-label, blinded endpoint analysis. The Lancet 369:1090-98 (March 31, 2007);4) Harris, The omega-3 index as a risk factor for coronary heart disease. Am J Clin Nutr 87(supp):1997S-2002S (2008);5) Davidson, et al. Efficacy and Tolerability of Adding Prescription Omega-3 Fatty Acids 4 g/d to Simvastatin 40 mg/d in Hypertriglyceridemic Patients: An 8-Week, Randomized, Double-Blind, Placebo-Controlled Study. Clinical Therapeutics 29(7): 1354-1367 (July)

Date Marked	Date Admitted	Number	Witness	Description
				2007). (ICOSAPENT_DFNDTS00007488-7529AMRN00598067AMRN00598068-76AMRN00598077-82AMRN00598083-96)
1/8/2020 <i>1/15/2020</i>	<i>1/15/2020</i>	1737		Tricor, in Physicians' Desk Reference 63 Ed. pp. 520-24 (2009)
1/8/2020 <i>1/15/2020</i>	<i>1/15/2020</i>	1738		Email between Braeckman and Bays re MARINE manuscript (AMRN02273377)
1/8/2020 <i>1/15/2020</i>	<i>1/15/2020</i>	1739		Bays, et al: Eicosapentaenoic Acid Ethyl Ester (AMR101) Theraoy in Patients with Very High Triglyceride Levels: The MARINE Trial. (AMRN01062083-114)
1/8/2020 <i>1/15/2020</i>	<i>1/15/2020</i>	1740		Email between Bays and Braeckman re MARINE manuscript (AMRN02903388-9)
1/8/2020 <i>1/15/2020</i>	<i>1/15/2020</i>	1741		Bays, et al. Eicosapentaenoic Acid Ethyl Ester (AMR101) Therapy in Patients with Very High Triglyceride Levels (from the Multi-center, Placebo-controlled, Randomized, double-blind, 12-week study with an open-label Extension [MARINE] Trial). Am J Cardiol 108:682-690 (2011). (AMRN00524816-24)
1/8/2020 <i>1/15/2020</i>	<i>1/15/2020</i>	1742		Declaration of Harold E. Bays Under 37 C.F.R. § 1.132, Application No. 12/702,889 (AMRN03058234-36)

Date Marked	Date Admitted	Number	Witness	Description
1/8/2020 1/15/2020	1/15/2020	1743		Draft of Declaration of Harold E. Bays Under 37 C.F.R. § 1.132, Application No. 12/702,889 (AMRN02056723-25)
1/8/2020		1744		Declaration of Harold E. Bays Under 37 C.F.R. § 1.132, Patent Application No. 12/702,889 (AMRN03059316-37)
1/8/2020 1/15/2020	1/15/2020	1745		Non-Final Rejection, Patent Application No. 12/702,889 (AMRN03059251-72)
1/8/2020		1746		Response to Non-Final Office Action Dated November 4, 2011, Patent Application No. 12/702,889 (AMRN03059282-315)
1/8/2020 1/15/2020	1/16/2020	1747		Bays, Clinical Overview of Omacor: A Concentrated Formulation of Omega-3 Polyunsaturated Fatty Acids. AM J Cardiol 98(Suppl):71i-76i (2006). (ICOSAPENT_DFNDTS00007482-87.)
1/8/2020		1748		Declaration III of Harold E. Bays Under 37 C.F.R. § 1.132, U.S. Patent Application No. 12/702,889. (AMRN03059815-29)
1/8/2020		1749		Response to Non-Final Office Action Dated March 2, 2012, Patent Application No. 12/702,889 (AMRN03059789-814)
1/8/2020 1/16/2020	1/16/2020	1750		Declaration of Harold E. Bays Under 37 C.F.R. § 1.132, Patent Application

Date Marked	Date Admitted	Number	Witness	Description
				No. 13/458,496 (AMRN03030162-71)
1/8/2020		1751		Aaron Berg Linkedin profile, https://www.linkedin.com/in/aaron-berg-7b13033/ last accessed 8/25/2018
				Amarin AMR101 in Hypertriglyceridemia, Non-confidential presentation (AMRN02165596-618)
1/8/2020		1753		Email between Shalaby, Thero, and Berg re Notes (AMRN00826821)
				Email between Berg, Padmanabhan, Boothe, and Boatman re Need more EPA feedback for JZs update for tomorrow, Send tonight? (AMRN02336076-78)
1/8/2020		1755		Email between Berg and Gilhooly re Central Files – Please look at (AMRN00893179)
				Presentation: Why Approve Now_WN (AMRN01493374-80)
1/8/2020		1757		Email between Sedlack and Berg re off label (AMRN00820445)
1/8/2020		1758		Email between Thero and Berg, re E Brinton attempts to set the record

Date Marked	Date Admitted	Number	Witness	Description
				straight – we need to discuss proactively having docs (at least steering committee members) appropriately media trained. (AMRN00828482)
1/8/2020		1759		Email between Berg, Bashe, Kuhl, and Jones re basf president interview re 03 (AMRN02344161-2)
1/8/2020		1760		Email between Berg, Bashe, and Kuhl re Market Research/supplement use (AMRN-02344006-7)
1/8/2020		1761		Email between Gilhooly, Berg, Mayes, Delacluyse, Sharp-Stenken, and Beck re Teva WAC and attaching Vascepa Net Price gen Lovaza slide
1/8/2020 1/21/2020	1/21/2020	1762	Hofmann	Email forward from Berg to Thero re generic Lovaza – perception versus reality
1/8/2020		1763		GSK Reduction in Lovaza Direct Selling Effort Leads to Lower Rx Volume (AMRN02160507)
1/8/2020		1764		Email between Bashe and Berg re Why Merck's Niacin Failure Will Scare Drug Researchers(AMRN00829792-96)
1/8/2020		1765		Email between Berg and Rigo re Market (AMRN00842379-81)

Date Marked	Date Admitted	Number	Witness	Description
1/8/2020		1766		Email between Gilhooly and Ameres re Generic WAC Price Communication
1/8/2020		1767		Email between Gilhooly, Berg, Galdo, Ameres, and Beck re some help
1/8/2020		1768		Email between Berg and Bashe re Tomorrow (AMRN02344070-1)
1/8/2020		1769		plot diagrams titled Sales Volume – Japan and Icosapent Unit Volume – Japan
1/8/2020		1770		Email between Berg and Kuhl re guidelines and OM-3 use (AMRN02344042-44)
1/8/2020		1771		Vascepa Celebrity Campaign (AMRN00303084)
1/21/2020	1/21/2020	1772	Hofmann	Vascepa Celebrity Brand Campaign (AMRN02352366)
1/21/2020	1/21/2020	1773	Hofmann	Amarin Commercial Update (AMRN00859728-74)

Date Marked	Date Admitted	Number	Witness	Description
1/8/2020		1774		Email between Berg and Thero re Amarin Potential News Later Today (AMRN02376107-9)
1/8/2020		1775		Email between Berg and Bashe re Kowa deal (AMRN02376664-5)
1/8/2020 1/21/2020	1/21/2020	1776	Hofmann	Amarin Sales and Marketing Update
1/8/2020		1777		Spreadsheet: Amarin Corporation 2013-14 Budget, Marketing
1/8/2020		1778		U.S. Patent 7,022,713
1/8/2020		1779		Elephant Analytics, Amarin: How The Co-Promotion Agreement With Kowa Affects Required Sales Targets. https://seekingalpha.com/article/2119273-amarin-how-the-co-promotion-agreement-with-kowa-affects-required-sales-targets , last accessed 07/24/2018
1/8/2020		1780		Email between Steier, Berg, Gilhooley, and Bruno re FYI – Amrin Media Coverage – Wednesday PM(AMRN00870842)
1/8/2020		1781		Native Spreadsheet re sales and price data Q1 2013 – Q2 2018

Date Marked	Date Admitted	Number	Witness	Description
				(AMRN03163817)
1/8/2020		1782		Native Spreadsheet re Quarterly Information Operating Loss Detail, SG&A Detail, and Net Sales Detail Q1-13 to Q2-18 (AMRN03163818)
1/8/2020		1783		Native Spreadsheet re Quarterly Information Operating Loss Detail, SG&A Detail, and Net Sales Detail Q1-13 to Q3-17 (AMRN03151451)
1/8/2020		1784		Native Spreadsheet re Quarterly Information Operating Loss Detail, SG&A Detail, and Net Sales Detail Q1-13 to Q2-17 (AMRN03151452)
1/8/2020		1785		Defendants' Joint Notice of Rule 30(b)(6) Deposition of Plaintiffs
1/8/2020		1786		Email between Park, Clement, and Others re Amarin Pharma Inc. et al. v. Hikma Pharmaceuticals USA Inc. et al., 16-cv-2525
1/8/2020		1787		Summary of 2013 and 2014 Commercial Spends and Vendors (excluding staffing) (AMRN00842922)
1/8/2020		1788		Vascepa marketing material

Date Marked	Date Admitted	Number	Witness	Description
1/8/2020		1789		KOL Expertise, Question and Answer (AMRN01493356-60)
1/8/2020		1790		Defendants' Joint Notice of Rule 30(b)(6) Deposition of Plaintiffs
1/8/2020		1791		Memorandum from Boal to Stewart re Idis Proposal for "Names Patient Sales" of Miraxion. (AMRN02099244-48)
1/8/2020		1792		Peet, et al. Two double-blind placebo-controlled pilot studies of eicosapentaenoic acid in the treatment of schizophrenia. Schizophrenia Research 49:243-251 (2001). (AMRN01650526-34)
1/15/2020	1/15/2020	1793		Email between Sedlack, Cooke, Cunningham, and Holmes re Minutes and Slides from EPA Triglycerides meeting – Thursday 20th December 2007 with attachments (AMRN02129382-413)
1/8/2020		1794		Email between Osterloh, Doogan, Wood, Cooke, Cunningham, Boal, and Shilling re EPA Hypertriglyceridemia Project Status and Investor Due Diligence with attachment (AMRN01671916-33)
1/8/2020		1795		EPA for Hypertriglyceridemia: Project Summary December 17, 2017 (AMRN02263071-74)
1/8/2020		1796		Email between Doogan, Manku, Osterloh, Cooke, and Lynch re Omacor

Date Marked	Date Admitted	Number	Witness	Description
				(Omega-3-Acid Ethyl Esters) – Current Clinical Trials (AMRN01672057-58)
1/8/2020 1/15/2020	1/15/2020	1797		Email between Manku, Cooke, Cunningham, and Lynch re EPA reduces cholesterol absorption from GIT tract and inhibits its synthesis in liver, attaching Mizuguchi 1992 article (AMRN01688512-9)
				Cosgrove, AMR101 Takes on Lovaza: Amarin enters final phase of testing for its promising fish oil medication for high cholesterol. Rodman publishing 2010. (AMRN02113623-4)
1/8/2020		1799		Email between Soni and Aralihalli attaching Saito 2008 article. (AMRN00624045-51)
				Amarin Next Generation Lipid Modification in Cardiovascular Disease: Investor Presentation (AMRN01171835-59)
1/8/2020 1/13/2020	1/13/2020	1800	Ketchum	Peet and Horrobin, A dose-ranging exploratory study of the effects of ethyl-eicosapentaenoate in patients with persistent schizophrenic symptoms. Journal of Psychiatric Research 36:7-18 (2002). (AMRN00731202-13)
1/8/2020		1802		Email between Manku, Cunningham, Holmes, and Cooke re Japanese publications – translations (AMRN01688238)
1/8/2020		1803		Email between Doogan, Rogan, and others re Investor Feedback attaching

Date Marked	Date Admitted	Number	Witness	Description
				spreadsheet (AMRN01566346-7)
1/8/2020		1804		Email between Crutchley, Bays, mcrichtui@ucsd.edu, and Hawkins re CONFIDENTIAL: Amarin Expert Panel Meeting for AMR-101 (ethyl-EPA) Meeting Package with attachments (AMRN00597991-8096)
				Email between Philip and Ketchum re Exec Summary RCM Series with attachment (AMRN01451526-639)
1/8/2020		1806		Kris-Etherton, et al. Fish Consumption, Fish Oil, Omega-3 Fatty Acids, and Cardiovascular Disease. Circulation 106:2747-2757 (2002).
1/8/2020		1807		Plaintiffs' Initial Disclosures
				Steve Ketchum Linkedin profile
1/8/2020 <i>1/13/2020</i>	<i>1/13/2020</i>	1809	<i>Ketchum</i>	Defendants' Joint Notice of Rule 30(b)(6) Deposition of Plaintiffs
1/8/2020		1810		Amarin AMR101 (icosapent ethyl) Capsules Investigator's Brochure Ed. 6.0 (AMRN03163819-937)

Date Marked	Date Admitted	Number	Witness	Description
1/8/2020		1811		Explanation of Changes Document AMR101, AMR101 Investigator's Brochure Version 6 (AMRN03163938-9)
1/8/2020		1812		Amarin Corporation PLC SEC Form 20-F
1/8/2020		1813		Presentation titled Amarin Ethyl EPA Hypertriglyceridemia Project Meeting (AMRN01224085-105)
1/8/2020 1/13/2020	1/13/2020	1814	Ketchum	Ethyl-EPA for Hypertriglyceridemia: Rationale and Outline of Proposed Development Program (AMRN00731672-682)
1/8/2020		1815		Email between Trefny and Stirtan attaching Lovaza label Dec2010 Tracked Changes (AMRN0786849-860)
1/8/2020 1/13/2020	1/13/2020	1816	Ketchum	P-IND 102,457, AMR101 Type B Meeting Information Package (AMRN02973472-592)
1/8/2020		1817		Amarin Corp PLC\UK Form 10-K Annual Report (ICOSAPENT_DFNNTS00003384-3403)
1/8/2020		1818		P-IND 102,457 AMR101 Request for Special Protocol Assessment: Phase 3 Study and final protocol AMR-01-01-0016(AMRN03019033-115)

Date Marked	Date Admitted	Number	Witness	Description
1/8/2020		1819		Email between Philip and Juliano attaching FDA EMDAC Amarin indication Brinton slides 10-16-31.1 (AMRN02714826-57)
1/8/2020		1820		Email between Philip and Ketchum re Exec Summary RCM Series (AMRN01451526-28)
1/8/2020		1821		Email between Philip and Ketchum re Regional Consultant Meetings Summaries (AMRN01451529)
1/8/2020		1822		Email between Sedlack, Kalinowski, Grandolfi, and Manku re Mochida selling API (AMRN01683571-72)
1/8/2020		1823		Email between Grandlofi and Soni attaching AMR101 vs. Epadel Chromalograms (Primera data).ppt (AMRN01535416-20)
1/8/2020		1824		Memorandum of Pre-IND Meeting Minutes (AMRN03107357-72)
1/8/2020		1825		Email between Bashe and Ketchum attaching Scientific Statement Against FDA Rescission of SPA for Vascepa (IPE) (AMRN02716805-21)
1/8/2020		1826		Email between Philip, Berg, and Thero re phone call dates/times attaching Brinton letter to FDA Commissioner (AMRN02343575-80)

Date Marked	Date Admitted	Number	Witness	Description
1/8/2020		1827		Email between Schultz and Soni re 3pm showing in New London, attaching Amarin Investor Presentation (AMRN01573009-38)
1/8/2020		1828		Amarin Next Generation Lipid Modification in Cardiovascular Disease: Investor Presentation
1/8/2020 1/13/2019	1/13/2020	1829	Ketchum	Amarin Cardioprotective Effects of Omega-3 Fatty Acids, AMR101 for Triglyceride Lowering (AMRN00731643)
1/8/2020		1830		Amarin Next Generation Lipid Modification in Cardiovascular Disease: Investor Presentation (AMRN01397826-57)
1/8/2020		1831		Rationale for Development of Ethyl-EPA for the Treatment of Hypertroglyceridemia (AMRN00204446-52)
1/8/2020		1832		Clinical Study Report: A Multi-Center, Prospective, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Effect of AMR101 on Cardiovascular Health and Mortality in Hypertriglyceridemic Patients with Cardiovascular Disease or at High Risk for Cardiovascular Disease (AMRN03164813-5069)
1/8/2020		1833		Clinical Study Report: A Multi-Center, Prospective, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Effect of AMR101 on Cardiovascular Health and Mortality in Hypertriglyceridemic

Date Marked	Date Admitted	Number	Witness	Description
				Patients with Cardiovascular Disease or at High Risk for Cardiovascular Disease: REDUCE-IT (Reduction of Cardiovascular Events with EPA – Intervention Trial. Final v 1.0 (AMRN03167963-8515)
1/8/2020		1834		Amarin Efficacy Data, AMR-01-01-0019 (AMRN03169860-3170135)
				Amarin Demographic Data, AMR-01-01-0019 (AMRN03168893-9177)
1/8/2020 <i>1/13/2020</i>	<i>1/13/2020</i>	1836	<i>Ketchum</i>	Letter to Dr. Rosenbraugh and Formal Dispute Resolution Project Manager re Formal Dispute Resolution Request, IND 103457 for Vascepa® (AMRN00111661-747)
1/8/2020 <i>1/13/2020</i>	<i>1/13/2020</i>	1837	<i>Ketchum</i>	Letter to Guettier re Formal Dispute Resolution Request, IND 103457 (S0077) (AMRN01478848)
1/8/2020 <i>1/13/2020</i>	<i>1/13/2020</i>	1838	<i>Ketchum</i>	Juliano and Ketchum, REDUCE-ITTM Presentation. (AMRN03156518-30)
1/8/2020		1839		Email between Ketchum, Juliano, Doyle, and Stirton re mineral oil issue(AMRN01472289-90)
1/8/2020		1840		Email between Ketchum and Berry re Preps for Monday 2pm team call (AMRN01455752)